Every 10-Q that NIKA PHARMACEUTICALS INC (NIKA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NIKA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NIKA filings page.
Nika Pharmaceuticals, Inc. reported no revenue for the three and six months ended June 30, 2026 and continues to operate in a pre-commercial stage. For the quarter, the company recorded a net loss of $19,694, bringing the six‑month net loss to $33,054 and the accumulated deficit to $9,037,063.
Total assets were $9,942, consisting almost entirely of cash and prepaid expenses, against total liabilities of $340,624, resulting in a stockholders’ deficit of $330,682 as of June 30, 2026. The company relied on $22,000 of non‑interest‑bearing related‑party loans to fund operating cash outflows of $20,957 in the first half of 2026.
Management states that recurring losses, no revenue, and dependence on related‑party financing raise substantial doubt about the ability to continue as a going concern. The report also identifies material weaknesses in internal control, including the lack of an audit committee and limited separation of duties, though no restatement was required for a timing error in prepaid expense amortization.
Nika Pharmaceuticals, Inc. reported another development-stage quarter with no revenue and a small net loss of $13,359 for the three months ended March 31, 2026, similar to the $12,945 loss a year earlier. Cash was very limited at $1,530, compared with current liabilities of $331,624, and the accumulated deficit reached $9,017,368, leading management to state there is substantial doubt about the company’s ability to continue as a going concern.
The business remains funded by non‑interest‑bearing, due‑on‑demand loans from related parties, including $13,000 advanced in the quarter. Nika continues to build its pharmaceutical platform through exclusive rights agreements, a controlling interest in Nika Europe Ltd., and a production agreement for ITV‑1 once a new factory in Bulgaria is completed. Internal controls over financial reporting were deemed ineffective due to a lack of an audit committee and limited separation of duties.
Nika Pharmaceuticals, Inc. filed its Q3 2025 report, showing no revenue and a net loss of $7,999 for the quarter ended September 30, 2025 (nine months: $39,309). Cash was $6,287 and current liabilities were $284,164, resulting in a stockholders’ deficit of $260,539. The company disclosed “substantial doubt” about its ability to continue as a going concern.
Operations were funded by related-party advances, including $45,000 during the nine months. At quarter-end, amounts due included $45,000 to Nika Europe, $205,164 to the CEO, and $34,000 to Nika Pharmaceuticals LTD, all non‑interest bearing and due on demand. The company continued accounting for a common control merger and issued 13,230,000 of the 204,205,027 common shares to be issued under that agreement. Common shares outstanding were 1,039,836,001 as of November 7, 2025.
Disclosure controls were deemed not effective due to a lack of an audit committee and separation of duties. The report also notes a production agreement with Nika Europe for ITV‑1 with a framework price of $580 per set, tied to factory completion.